U.S. FDA· @FDA · X·· 12 天前精选AI 评分40
AI 导读
FDA表示,针对95%仍无获批治疗方案的罕见病患者,该机构正通过新的罕见病框架计划(Rare Disease Framework Initiative)推动罕见病药物开发。代理局长Kyle Diamantas介绍了这一计划,称其旨在为罕见病家庭带来答案、行动与希望。
推荐理由
FDA代理局长介绍罕见病药物开发新框架,读者可了解该机构在罕见病审评方向上的政策动向。
正文
For the 95% of rare disease patients still without an approved treatment, FDA is working for you.
Acting Commissioner Kyle Diamantas shares how FDA is transforming rare disease drug development through the new Rare Disease Framework Initiative. Because every family deserves answers, action, and hope. https://www.fda.gov/news-events/fda-voices/delivering-answers-and-hope-rare-disease-families
来源:U.S. FDA · x.com